Hikma Pharmaceuticals generic version of Advair has hit a stumbling block with the FDA. Source: BioSpace

Biogen is buying Pfizer’s PF-04958242, a first-in-class, Phase IIb-ready drug to treat several neurological and psychiatric diseases, including schizophrenia. Source: BioSpace

After a hard-fought battle to win the green light for Exondys 51 from the U.S. Food and Drug Administration, Sarepta Therapeutics is planning on seeking approval of a second treatment…

Shares of weight-loss drugmaker Orexigen Therapeutics are in free-fall this morning after the company announced it filed for bankruptcy. Source: BioSpace

Realm Therapeutics announced today that its PR013, failed to show efficacy in its Phase II trial for allergic conjunctivitis. Source: BioSpace

Abiomed, Inc. will pay the U.S. government $3.1 million to settle allegations that the company sought to influence doctors to use the company’s line of heart pumps in a kickback…

MyoKardia Inc. revealed positive results from a mid-stage obstructive hypertrophic cardiomyopathy trial. Source: BioSpace

Xeris Pharmaceuticals secured $45 million in a Term Loan and Securities Agreement with Silicon Valley Bank and Oxford Finance, as well as closing a Series C financing with an additional…

AcelRx Pharmaceuticals plans to resubmit the NDA for Dsuvia in the second quarter of this year. Source: BioSpace

Voyager Therapeutics released longer-term data from its ongoing Phase Ib clinical trial of VY-AADC in advanced Parkinson’s disease. Source: BioSpace